Cash-pay compounded and insurance-routed brand medication are two different paths to GLP-1 therapy. The right choice depends mostly on your insurance situation. Compounded semaglutide and tirzepatide are cash-pay and predictable, but they are not FDA-approved and are not the same product as Wegovy or Zepbound. Insurance routes you to brand medication, but what you pay varies widely. A third path now sits in between: brand self-pay programs from the manufacturers.
Side-by-side
| Dimension | Cash-pay compounded | Insurance + branded |
|---|---|---|
| Semaglutide | $49–$169/mo across 22 compounded semaglutide programs (median $94) | Copay set by your plan (as little as $25/mo with Novo Nordisk's commercial savings offer); Wegovy list price $1,349.02 a package |
| Tirzepatide | $86–$280/mo across 28 compounded tirzepatide programs (median $144) | Copay set by your plan; Zepbound self-pay $299–$449/mo through LillyDirect |
| FDA approval | Not FDA-approved | FDA-approved brand products |
| Prior authorization | None | Often required |
Index figures are the lowest all-in monthly price we found for each program, read October 15, 2026, including conditional and "as low as" prices as printed. Brand prices: novocare.com (Wegovy) and Lilly's Zepbound savings page, read October 15, 2026.
Who should pick Cash-pay compounded
Patients without insurance for GLP-1 medications; patients with insurance that excludes weight management; patients who want a predictable monthly cost and accept that compounded medication is not FDA-approved.
Who should pick Insurance + branded
Patients with insurance covering Wegovy or Zepbound at a meaningful copay; patients who want an FDA-approved product with indication-specific labeling. Eligible Medicare Part D enrollees can use CMS's Medicare GLP-1 Bridge, a $50 copay from July 1, 2026 to December 31, 2027.
Frequently asked
How to decide?
Call your insurer's member services. Ask: (1) is the medication on formulary, (2) what tier, (3) PA criteria, (4) expected copay. If the copay is $25–$100/mo with reasonable PA, the insurance route usually makes sense. If you are denied or the copay is $200+, compare compounded cash prices with brand self-pay prices (Wegovy pen $349/mo through NovoCare; Zepbound $299–$449/mo through LillyDirect, read October 15, 2026).
Can I switch?
Yes, with your clinician's guidance. Some patients start cash-pay for faster access, then switch to an insurance-covered brand medication once prior authorization is approved. Compounded and brand products are not interchangeable dose for dose, so the clinician sets the new dose.
Out-of-pocket caps?
Most commercial plans have annual out-of-pocket maximums. If you're approaching it for other reasons, branded with high copay may net out cheaper.